BioCentury
ARTICLE | Clinical News

Voclosporin misses endpoint in uveitis Phase III

December 28, 2012 12:48 AM UTC

Isotechnika Pharma Inc. (TSX:ISA) said Luveniq voclosporin missed the primary endpoint in a Phase III trial to treat non-infectious uveitis. Partner Lux Biosciences Inc. (Jersey City, N.J.) was conducting the trial to address FDA's request for an additional pivotal trial in a 2010 complete response letter for Luveniq. Lux has exclusive, worldwide rights from Isotechnika to Luveniq for ophthalmic indications. ...